A new medication-based prediction score for postoperative delirium in surgical patients: Development and proof of feasibility in a retrospective patient cohort.

IF 1.5 4区 医学 Q4 CHEMISTRY, MEDICINAL
Pharmazie Pub Date : 2022-10-01 DOI:10.1691/ph.2022.2438
V Hindelang, K Dimitriadis, T Saller, K Golla, H Mannell, M J Hug, D Strobach
{"title":"A new medication-based prediction score for postoperative delirium in surgical patients: Development and proof of feasibility in a retrospective patient cohort.","authors":"V Hindelang,&nbsp;K Dimitriadis,&nbsp;T Saller,&nbsp;K Golla,&nbsp;H Mannell,&nbsp;M J Hug,&nbsp;D Strobach","doi":"10.1691/ph.2022.2438","DOIUrl":null,"url":null,"abstract":"<p><p>Structured risk screening for postoperative delirium (POD) considering prehospital medication is not established. We aimed to develop a POD-risk prediction score based on known risk factors and delirium-risk increasing drugs to be used by pharmacists during medication reconciliation at hospital admission, and to test for feasibility in a retrospective cohort of surgical patients. Therefore, established POD-risk factors and drugs were extracted from the literature and a score was generated. Following this, the score was tested for feasibility in a retrospective 3-month-cohort of surgical patients. For patients with higher scores suggesting higher probability of POD, patient charts were screened for documentation of POD. For development of the score, the following POD-risk factors were defined and points assigned for score calculation: age (≥65 years=1 point/≥75 years=2), male sex (1), renal insufficiency (RI; 1), hepatic impairment (HI; Model-of-endstage-liver-disease (MELD) 10-14=1/≥15=2), delirium-risk increasing drugs (1 point per drug class), anticholinergic drug burden (ACB; ≥3=1). In the retrospective test cohort of 1174 surgical patients these factors concerned: age ≥65 years 567 patients (48%)/≥75 years 303 (26%), male 652 (55%), RI 238 (20%), MELD 10-14 106 (9%)/≥15 65 (5%), ≥ 1 delirium-risk increasing drug 418 (36%), ACB ≥3 106 (9%). The median POD-risk prediction score was 2 (range 0-9). Of 146 patients (12%) with a score ≥ 5, POD was documented for 43 (30%), no evidence for POD for 91 (62%) and data inconclusive for 12 (8%). For scores of ≥ 7, POD was documented for 50% of the patients with sufficient POD documentation. Overall, POD documentation was poor. To summarize, we developed and successfully tested the feasibility of a POD-prediction-score assessable by pharmacists at medication reconciliation at hospital admission.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"77 10","pages":"302-306"},"PeriodicalIF":1.5000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1691/ph.2022.2438","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Structured risk screening for postoperative delirium (POD) considering prehospital medication is not established. We aimed to develop a POD-risk prediction score based on known risk factors and delirium-risk increasing drugs to be used by pharmacists during medication reconciliation at hospital admission, and to test for feasibility in a retrospective cohort of surgical patients. Therefore, established POD-risk factors and drugs were extracted from the literature and a score was generated. Following this, the score was tested for feasibility in a retrospective 3-month-cohort of surgical patients. For patients with higher scores suggesting higher probability of POD, patient charts were screened for documentation of POD. For development of the score, the following POD-risk factors were defined and points assigned for score calculation: age (≥65 years=1 point/≥75 years=2), male sex (1), renal insufficiency (RI; 1), hepatic impairment (HI; Model-of-endstage-liver-disease (MELD) 10-14=1/≥15=2), delirium-risk increasing drugs (1 point per drug class), anticholinergic drug burden (ACB; ≥3=1). In the retrospective test cohort of 1174 surgical patients these factors concerned: age ≥65 years 567 patients (48%)/≥75 years 303 (26%), male 652 (55%), RI 238 (20%), MELD 10-14 106 (9%)/≥15 65 (5%), ≥ 1 delirium-risk increasing drug 418 (36%), ACB ≥3 106 (9%). The median POD-risk prediction score was 2 (range 0-9). Of 146 patients (12%) with a score ≥ 5, POD was documented for 43 (30%), no evidence for POD for 91 (62%) and data inconclusive for 12 (8%). For scores of ≥ 7, POD was documented for 50% of the patients with sufficient POD documentation. Overall, POD documentation was poor. To summarize, we developed and successfully tested the feasibility of a POD-prediction-score assessable by pharmacists at medication reconciliation at hospital admission.

一种新的基于药物的手术患者术后谵妄预测评分:在回顾性患者队列中的发展和可行性证明。
考虑院前用药的术后谵妄(POD)的结构化风险筛查尚未建立。我们的目的是建立一个基于已知危险因素和谵妄风险增加药物的pod风险预测评分,供药剂师在住院时进行药物调节时使用,并在手术患者的回顾性队列中测试其可行性。因此,从文献中提取已确定的pod危险因素和药物,并进行评分。随后,在3个月的外科患者回顾性队列中测试评分的可行性。对于得分越高的患者,POD的可能性越高,筛选患者病历以记录POD。在制定评分时,定义了以下pod危险因素并分配了积分用于评分计算:年龄(≥65岁=1分/≥75岁=2分)、男性(1分)、肾功能不全(RI;1)肝损害(HI);终末期肝病模型(MELD) 10-14=1/≥15=2),谵妄风险增加药物(每类药物1分),抗胆碱能药物负担(ACB;≥3 = 1)。在1174例外科患者的回顾性试验队列中,这些因素涉及:年龄≥65岁567例(48%)/≥75岁303例(26%),男性652例(55%),RI 238例(20%),MELD 10-14 106例(9%)/≥15 65例(5%),≥1种增加精神错乱风险的药物418例(36%),ACB≥3 106例(9%)。pod风险预测评分中位数为2分(范围0-9)。在评分≥5的146例患者(12%)中,43例(30%)被记录为POD, 91例(62%)无证据证明POD, 12例(8%)数据不确定。对于评分≥7分的患者,50%的患者有足够的POD记录。总的来说,POD文档很差。总之,我们开发并成功测试了pod预测评分的可行性,该评分可由药剂师在住院时进行药物和解评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmazie
Pharmazie 医学-化学综合
CiteScore
3.10
自引率
0.00%
发文量
56
审稿时长
1.2 months
期刊介绍: The journal DiePharmazie publishs reviews, experimental studies, letters to the editor, as well as book reviews. The following fields of pharmacy are covered: Pharmaceutical and medicinal chemistry; Pharmaceutical analysis and drug control; Pharmaceutical technolgy; Biopharmacy (biopharmaceutics, pharmacokinetics, biotransformation); Experimental and clinical pharmacology; Pharmaceutical biology (pharmacognosy); Clinical pharmacy; History of pharmacy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信